Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer.

HPV-positive OPSCC combined modality therapy double immune checkpoint inhibition head and neck neoplasms immunotherapy induction therapy organ preservation

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
19 Apr 2021
Historique:
received: 31 01 2021
revised: 20 03 2021
accepted: 14 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

To determine whether a single dose of double immune checkpoint blockade (induction chemoimmunotherapy (ICIT)) adds benefit to induction single-cycle platinum doublet (induction chemotherapy (IC)) in locally advanced head and neck squamous cell carcinoma (HNSCC), patients treated with cisplatin 30 mg/m

Identifiants

pubmed: 33921668
pii: cancers13081959
doi: 10.3390/cancers13081959
pmc: PMC8073509
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Natl Cancer Inst. 2009 Apr 1;101(7):498-506
pubmed: 19318632
N Engl J Med. 2007 Oct 25;357(17):1695-704
pubmed: 17960012
Ann Oncol. 2017 Sep 1;28(9):2206-2212
pubmed: 28911070
J Clin Oncol. 2016 Dec;34(34):4132-4141
pubmed: 27863190
Clin Cancer Res. 2020 Jul 1;26(13):3211-3219
pubmed: 32269052
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
JAMA Oncol. 2019 Feb 1;5(2):195-203
pubmed: 30383184
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33023982
Eur J Cancer. 2019 Jan;107:142-152
pubmed: 30576970
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
J Clin Oncol. 2017 Feb 10;35(5):490-497
pubmed: 28029303
Lancet Oncol. 2013 Mar;14(3):257-64
pubmed: 23414589
J Clin Oncol. 2006 Feb 1;24(4):593-8
pubmed: 16380415
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Curr Oncol Rep. 2020 Jun 29;22(8):81
pubmed: 32602047
N Engl J Med. 2007 Oct 25;357(17):1705-15
pubmed: 17960013
Ann Oncol. 2012 Oct;23(10):2708-2714
pubmed: 22492697
Ann Oncol. 2020 Jul;31(7):942-950
pubmed: 32294530
J Clin Oncol. 2018 Nov 1;36(31):3077-3083
pubmed: 30016178
Strahlenther Onkol. 2020 Jun;196(6):522-529
pubmed: 32006068
N Engl J Med. 2003 Nov 27;349(22):2091-8
pubmed: 14645636
Eur Arch Otorhinolaryngol. 2020 Jan;277(1):245-254
pubmed: 31583430
J Clin Oncol. 2008 Jul 1;26(19):3138-46
pubmed: 18474879
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
J Clin Oncol. 2005 Dec 1;23(34):8636-45
pubmed: 16275937
Strahlenther Onkol. 2014 Feb;190(2):192-8
pubmed: 24362503
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207
Strahlenther Onkol. 2011 Jan;187(1):15-22
pubmed: 21234526
Methods Enzymol. 2020;632:389-415
pubmed: 32000906
Ann Oncol. 2017 Aug 1;28(8):1917-1922
pubmed: 28498880

Auteurs

Sabine Semrau (S)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Antoniu-Oreste Gostian (AO)

Department of Otorhinolaryngology-Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Maximilian Traxdorf (M)

Department of Otorhinolaryngology-Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Markus Eckstein (M)

Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Sandra Rutzner (S)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Jens von der Grün (J)

Department of Radiotherapy and Oncology, Goethe University Frankfurt, Frankfurt am Main, 60323 Hessen, Germany.

Thomas Illmer (T)

Medical Oncology Clinic Dresden Freiberg, Dresden, 01307 Sachsen, Germany.

Matthias Hautmann (M)

Department of Radiation Oncology, Universität Regensburg, Regensburg, 93040 Bayern, Germany.

Gunther Klautke (G)

Department of Radiation Oncology, Chemnitz Hospital, Chemnitz, 09112 Sachsen, Germany.

Simon Laban (S)

Department of Otorhinolaryngology and Head & Neck Surgery, Universitätsklinikum Ulm, Ulm, 89081 Baden-Württemberg, Germany.

Thomas Brunner (T)

Department of Radiation Oncology, Otto von Guericke Universität Magdeburg, Sachsen-Anhalt, 39120 Magdeburg, Germany.

Bálint Tamaskovics (B)

Department of Radiation Oncology, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, 40210 Nordrhein-Westfalen, Germany.

Benjamin Frey (B)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Jian-Guo Zhou (JG)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.
Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.

Carol-Immanuel Geppert (CI)

Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Arndt Hartmann (A)

Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Panagiotis Balermpas (P)

Department of Radiotherapy and Oncology, Goethe University Frankfurt, Frankfurt am Main, 60323 Hessen, Germany.

Wilfried Budach (W)

Department of Radiation Oncology, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, 40210 Nordrhein-Westfalen, Germany.

Udo Gaipl (U)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Heinrich Iro (H)

Department of Otorhinolaryngology-Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Rainer Fietkau (R)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Markus Hecht (M)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Classifications MeSH